neoSurgical Opens U.S. Headquarters and Launches New Medical Device for Minimally Invasive and Laparoscopic Surgery at Minimally Invasive Surgery Week
neoSurgical, an international medical device company focused on advancing safer and simpler solutions for Laparoscopic and Minimally Invasive Surgery (MIS), announces today that it has opened its U.S. headquarters in Chicago and will debut its flagship product neoClose at Minimally Invasive Surgery Week on August 28 in booth #6. Minimally Invasive Surgery Week is sponsored by the Society of Laparoendoscopic Surgeons (SLS) and affiliated societies and is being held at the Hyatt Regency in Reston, VA.
neoClose is an innovative new FDA-approved device designed to overcome the challenges of quickly, simply and effectively closing any port or access site in the abdominal wall following keyhole surgery. With current methods, closure can be technically challenging, requires user skill and does not always result in consistent outcomes for the patient. Surgeons have continually grappled with locating sutures within the abdomen as well as managing post-operative issues such as pain & herniation among other potential complications arising from current techniques.
The neoClose device consists of an AccuGuide that aids the accurate delivery of a bio-absorbable PGA suture and attached bio-absorbable AutoAnchor using the trocar as the reference point that swiftly and easily closes the wound and offers a consistent positive outcome to both the surgeon and the patient. The device can be deployed under full pneumo/inflation in three simple steps in under one minute.
"We're very excited to announce the news of our U.S. office in Chicago and to be debuting neoClose at the SLS expo where we'll have the opportunity to provide hands-on demonstrations showcasing the simplicity and superiority of the product," said Barry Russell, neoSurgical Founder and CEO. "Overcoming challenges with innovative technology that makes surgical procedures simpler, faster and more efficient is our main focus. In fact, feedback from surgeons in response to neoClose has been '... it's so simple, why didn't I think of that!' Conceiving and developing devices that work more simply than current options is at the kernel of what we do. It is always more challenging to engineer a device to the point where everyone who handles it sees the benefits and appreciates the simplicity," he added.
Initially launched in Europe, neoClose is FDA approved and commercially available to surgeons in the U.S. through neoSurgical's expanding distributor network and will be available nationally as the neoSurgical team ramps up its USA plans in the coming months.